In Vitro Effects on MCF-7 Breast Cancer Cells Of Signal Transduction Inhibitor/Tamoxifen/Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin
- 284 Downloads
To determine the in vitro effects of simultaneously administered LY29400, PD98059, tamoxifen and eicosapentaenoic acid (EPA) on breast cancer cells, and determine their transcutaneous delivery.
Growth assays were performed on MCF-7 cells challenged with IC50 and permeated concentrations of PD98059, LY294002 and tamoxifen firstly in isolation then combined. Permeation studies were performed using PD98059 and LY294002 (singly or simultaneously) in DMSO then fish oil, with enhancers. Immunocytochemical detection of phospho-MAPK, phospho-Akt, total COX-2 and Ki-67 was performed.
When applied singly, fluxes of PD98059 and LY294002 were 0.09 ± 0.008 and 0.14 ± 0.045 μg cm−2 h−1, respectively; applied simultaneously, 0.18 ± 0.045 and 0.49 ± 0.051 μg cm−2 h−1. Permeated concentrations of PD98059 and LY294002 reduced growth to 13.78 ± 0.63%. Fish oil plus 2.5% DMSO/ethanol allowed 5.96 ± 0.9 and 7.7 ± 1.2 μg cm−2 of PD98059 and LY294002 to permeate after 48 h.
PD98059 and LY294002 permeate excised skin at therapeutically useful rates, and also demonstrate growth inhibitory effects on MCF-7 cancer cells. Synergism was noted in co-transport across skin and activity against cancer cells. A formulation based on fish oil is potentially skin friendly; simultaneous permeation of EPA provides further anti-cancer action.
KEY WORDSbreast cancer EPA signal transduction inhibitor tamoxifen transcutaneous delivery
epidermal growth factor receptor
- 2.R. B. Riggins, K. S. Thomas, H. Q. Ta, J. Wen, R. J. Davis, N. R. Schuh, S. S. Donelan, K. A. Owen, M. A. Gibson, M. A. Shupnik, C. M. Silva, S. J. Parsons, R. Clarke, and A. A. Bouton. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. 66:7007–7015 (2006).PubMedCrossRefGoogle Scholar
- 4.J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden, J. M. W. Gee, M. E. Harper, D. Barrow, A. E. Wakeling, and R. I. Nicholson. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044 (2003).PubMedCrossRefGoogle Scholar
- 9.M. Sun, J. E. Paciga, R. I. Feldman, Z.-Q. Yuan, D. Coppola, Y. Y. Lu, S. A. Shelley, S. V. Nicosia, and J. Q. Cheng. Phosphatidylinositol-3-OH kinase (P13K)/AKT2, activated in breast cancer, regulates and is induced by Estrogen Receptor (ER) via interaction between ER and PI3K. Cancer Res. 61:5985–5991 (2001).PubMedGoogle Scholar
- 13.S. Ho, R. J. Calder, C. M. Heard, and C. P. Thomas. In vitro transcutaneous delivery of tamoxifen and γ linolenic acid from a borage oil formulation containing ethanol and 1,8-cineole. J. Pharm. Pharmacol. 56:1–8 (2004).Google Scholar
- 14.A. C. Williams. Topical and Transdermal Drug Delivery, Pharmaceutical, London, 2004.Google Scholar
- 16.M. L. Parrett, R. E. Harris, and F. S. Joarder. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 11:503–507 (1997).Google Scholar
- 17.P. J. Wild, L. A. Kunz-Schughart, F. Bataille, R. Simon, G. Sauter, M. Mihatsch, and A. Hartmann. Strong COX-2 overexpression in breast and prostate cancer—a potential therapeutic target. Proc. Am. Assoc. Cancer Res. 45:3059 (2004).Google Scholar
- 18.T. L. Larkins, M. Nowell, T. Wallace, and G. L. Sanford. Inhibition of COX-2 attenuates the motility and invasion of breast cancer cells. Proc. Am. Assoc. Cancer Res. 46:3059 (2005).Google Scholar
- 19.E. W. Thompson, and M. Waltham. Stromal MMP targets for human breast cancer growth and progression. Tumor biology. Proc. Am. Assoc. Cancer Res. 47:937–939 (2006).Google Scholar
- 25.C. M. Heard, J. L. Harwood, P. Maguire, G. McNaughton, and W. J. Pugh. Simultaneous penetration of NSAID and essential fatty acid esters as a dual-action anti-arthritis therapy. In K. R. Brain, and K. Walters (eds.), Perspectives in Percutaneous Penetration, Vol 8a, STS, Cardiff, 2002, p. 93.Google Scholar
- 26.C. M. Heard, C. Congiatu, S. J. Gallagher, J. L. Harwood, C. Karia, C. McGuigan, M. Nemcova, T. Nouskova, and C. P. Thomas. Preferential π complexation between tamoxifen and borage oil/γ linolenic acid: transcutaneous delivery and NMR spectral modulation. Int. J. Pharm. 302:47–55 (2005).PubMedCrossRefGoogle Scholar